CJC-1295 without DAC + Ipamorelin Blend

CJC-1295 without DAC + Ipamorelin – Synergistic GH Research Peptide Blend

Short Description: A synergistic blend of CJC-1295 (no DAC) and Ipamorelin studied for dual-pathway stimulation of GH release via GHRH and ghrelin receptor activation in in-vitro models.

The CJC-1295 without DAC + Ipamorelin Blend is a dual-peptide research formulation combining a Growth Hormone–Releasing Hormone (GHRH) analogue and a Growth Hormone–Releasing Peptide (GHRP) to create a synergistic model for the study of growth hormone (GH) regulation. This combination enables the investigation of both GHRH receptor–mediated and ghrelin receptor (GHSR)–mediated GH release mechanisms.

This product is produced under stringent laboratory protocols and tested using High-Performance Liquid Chromatography (HPLC) to confirm a purity of ≥99%. It is formulated as a lyophilized powder for use in controlled in-vitro endocrinological and biochemical research.

Blend Composition

• CJC-1295 without DAC – 5 mg: GHRH analogue studied for supporting natural, pulsatile GH release via GHRH receptor activation.

• Ipamorelin – 5 mg: GHRP studied for selective activation of ghrelin receptors (GHSR) with minimal impact on cortisol and prolactin pathways.

Key Specifications

• Name: CJC-1295 without DAC + Ipamorelin Blend

• Total Content: 10 mg (5 mg CJC-1295 without DAC + 5 mg Ipamorelin)

• Type: Combination of GHRH and GHRP analogues

• Form: Lyophilized Powder

• Purity: ≥99% (HPLC tested)

• Storage: Store refrigerated, protected from light and moisture

Research Applications & Benefits

• Used in research on growth hormone secretion via dual receptor pathways.

• Enables investigation of GHRH and GHSR signaling synergy.

• Ideal for studies focused on metabolic regulation and GH stimulation protocols.

• Supplied in lyophilized form for long-term storage and reproducibility.

For research use only. Not for human or veterinary consumption.